Assessing the cardiovascular and potassium lowering effects of levalbuterol compared to albuterol: a randomized control trial
Frontiers in Cardiovascular Medicine · 08.12.2025 · 12
DOI: 10.3389/fcvm.2025.1463999 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 08.12.2025. Verfasst von Baraa Shebli und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Department of Internal Medicine, Division of Cardiology, University of Aleppo, Aleppo University Hospital, Aleppo, Syria. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Beta-agonists like Levalbuterol and Albuterol are used in the treatment of Hyperkalemia. However, few studies in the medical literature have directly compared the cardiac effects and potassium-lowering efficacy of levalbuterol and albuterol, yielding inconclusive results. Understanding the cardiovascular effects and potassium-lowering abilities of these medications in hyperkalemic patients is crucial for optimizing treatment strategies and minimizing adverse events.
Methods
This randomized controlled trial conducted at Aleppo University Hospital in Syria aimed to compare the cardiovascular and potassium-lowering effects of Levalbuterol vs. Albuterol in hyperkalemic patients. The study, carried out between October 2021 and February 2022, utilized a single-center single-blinded two-armed design with patients randomized using a computer-generated sequence and block randomization method.
Results
The results showed no significant difference in mean HR change between Levalbuterol and Albuterol groups at 30 min, nor in the change in potassium serum levels at 90 min. Both drugs exhibited similar patterns in HR changes over time and blood pressure variations at different points. Despite limitations in data collection for side effects, the reported symptoms in both groups were consistent with known side effects of beta-agonists, with tremors and nervousness being the most commonly reported.
Conclusion
Our study provides the first direct insights into the effects of Levalbuterol and Albuterol on heart rate, potassium levels, and blood pressure which would be very important in specific cases such as in patients with heart failure. Both medications showed similar patterns in heart rate changes, potassium levels, and blood pressure variations at different time points. Clinical Trial Registration Clinicaltrials.gov , identifier NCT05173584.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, Department of Internal Medicine, Division of Cardiology, University of Aleppo, Aleppo University Hospital, Aleppo, Syria.
- Faculty of Medicine, University of Aleppo, Aleppo University Hospital, Aleppo, Syria.
- Faculty of Medicine, Department of Internal Medicine, University of Aleppo, Aleppo University Hospital, Aleppo, Syria.
- Department of Mathematical Statistics, Faculty of Science, University of Aleppo, Aleppo, Syria.
Zitieren
APA
Shebli, B., Ghabally, M., Shabouk, M. B., Arnaout, A. Y., Zeina, M. B., & Malhis, M. (2025). Assessing the cardiovascular and potassium lowering effects of levalbuterol compared to albuterol: a randomized control trial. Frontiers in Cardiovascular Medicine, 12. https://doi.org/10.3389/fcvm.2025.1463999
Vancouver
Shebli B, Ghabally M, Shabouk MB, Arnaout AY, Zeina MB, Malhis M. Assessing the cardiovascular and potassium lowering effects of levalbuterol compared to albuterol: a randomized control trial. Frontiers in Cardiovascular Medicine. 2025;12. doi:10.3389/fcvm.2025.1463999
BibTeX
@article{Shebli2025,
author = {Shebli, Baraa and Ghabally, Mike and Shabouk, Muhammad Besher and Arnaout, Ahmad Yamen and Zeina, Mohamed Besher and Malhis, Mahmoud},
title = {Assessing the cardiovascular and potassium lowering effects of levalbuterol compared to albuterol: a randomized control trial},
journal = {Frontiers in Cardiovascular Medicine},
year = {2025},
volume = {12},
doi = {10.3389/fcvm.2025.1463999}
}
EUVIMED